Cancer hijacks the microbiome to glut itself on glucose

Leukemia actively undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

Results published today in the New England Journal of Medicine and presented at the World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.

Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer

Entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) shows response rate of 77.4 percent, with median duration of response of 24.6 months

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

The path to a therapy against ΔNp63α seems clear: activate TGFB2 and RHOA.

Colorado Cancer Screening Program helps underinsured/underserved patients navigate the healthcare system to link to cancer screening

With a decade of success to increase colon cancer screening rates in Colorado, the Colorado Colorectal Screening Program is getting a facelift as the Colorado Cancer Screening Program (CCSP). In an effort to provide “whole-person cancer screening” to underserved and...

Latest News from the University of Colorado Cancer Center

@CUCancerCenter on Twitter